The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.
Saved in:
| Title: | The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy. |
|---|---|
| Authors: | Bornes L; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Winden LJ; Laboratory of Clinical Chemistry and Hematology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Geurts VCM; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Bruijn B; VIB Center for Cancer Biology, KU Leuven Department of Oncology, Leuven, Belgium., Azarang L; Biostatistics Centre & Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lanfermeijer M; Laboratory of Clinical Chemistry and Hematology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Caruso M; VIB Center for Cancer Biology, KU Leuven Department of Oncology, Leuven, Belgium., Proost N; Mouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Boeije M; Mouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lohuis JO; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Belthier G; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Noguera Delgado E; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Gruil N; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Kroep JR; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., van de Ven M; Mouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Menezes R; Biostatistics Centre & Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wesseling J; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands., Kok M; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Linn S; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, Utrecht University Medical Center, Utrecht, the Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Rossum HH; Laboratory of Clinical Chemistry and Hematology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Scheele CLGJ; VIB Center for Cancer Biology, KU Leuven Department of Oncology, Leuven, Belgium. colinda.scheele@kuleuven.be., van Rheenen J; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. j.v.rheenen@nki.nl. |
| Source: | Nature [Nature] 2025 Jan; Vol. 637 (8044), pp. 195-204. Date of Electronic Publication: 2024 Dec 04. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
